YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials […]
YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials […]
MELBOURNE, Australia–(BUSINESS WIRE)–Global fintech Airwallex has embarked on a pivotal partnership with the University of Melbourne, which will help build the next generation of Australian […]
ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting BOSTON & DAEJEON, South […]
SINGAPORE – Media OutReach – 1 November 2022 – Singapore-based Lightnet Group (“Lightnet”) announced today the completion of Raffles Family Office’s (“Raffles FO”) strategic investment. […]
INDIANAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) — Kite Realty Group Trust (NYSE: KRG) announced today the release of its inaugural Corporate Responsibility Report, which provides […]
Boomi helps top Western Australian university make data more accessible for improved staff and student online experience, while creating efficiencies in the technology department Edith […]
TAIPEI, Taiwan–(BUSINESS WIRE)–The Taiwan Textile Federation recently released an explainer video detailing the latest developments of one of the country’s most innovative sectors – “Discover […]
Copyright © 2026 | Miscw.com